Clinical Trials Logo
  1. Home
  2. Migraine Disease
  3. NCT01004835
  4. Details
NCT01004835 Clinical Trial

The Migraine and Pain Study GeneBank at Scripps Clinic Registry (MAPS)

Migraine Disease Clinical Trial

— MAPS  

Official title:
The Migraine and Pain Study GeneBank at Scripps Clinic Registry (MAPS)

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01004835
Other study ID # HSC# 08-5099
Secondary ID
Status Completed
Phase N/A
First received October 29, 2009
Last updated October 14, 2015
Start date January 2009
Est. completion date May 2015

Study information
Verified date October 2015
Source Scripps Translational Science Institute
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The objective of this study is to obtain blood or saliva samples to define genes for migraine and pain diseases.

Description:

It is estimated that over one-third of the world's population suffers from persistent or recurrent pain. Migraine is highly heritable and the majority of juveniles who suffer from the disorder have a mother or father who also have the disease. The blood or saliva samples will go through DNA analysis and be sequenced for candidate genes or subjected to whole-genome sequencing. By creating a MAPS GeneBank from these patients' blood/saliva donations we will ultimately be able to define genes for migraine and pain diseases.

Recruitment information / eligibility
Status Completed
Enrollment 61
Est. completion date May 2015
Est. primary completion date May 2015
Accepts healthy volunteers No
Gender Both
Age group 10 Years and older
Eligibility Inclusion Criteria:

1. Family members (genetic duo or trio), consisting of an adolescent 10 to 18 years of age and at least one of their biologic parents willing to be participate in trial

2. Adolescent and at least 1 biologic parent with Migraine diagnosis confirmed by Dr. Christy Jackson

3. Is reliable, cooperative and willing to comply with all protocol-specified procedures and/or sub-study if consented

4. Able to understand and grant informed consent

Exclusion Criteria:

1. Patient has been previously enrolled in the MAP GeneBank at Scripps Clinic Registry

2. Has a significant chronic medical condition (i.e.chronic meningitis or a secondary origin/cause of headache) which, in the investigator's option, may interfere with the patient's optimal participation in the study

3. Treatment with any investigational agents or devices within 30 days preceding enrollment in the study

4. Has undergone ECT within 90 days preceding enrollment in the study

Study Design

Observational Model: Family-Based

Related Conditions & MeSH terms

Locations
Country Name City State
United States Scrippshealth La Jolla California

Sponsors (1)
Lead Sponsor Collaborator
Scripps Translational Science Institute

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Gene identification By creating a MAPS GeneBank from these patients' blood/saliva donations we will ultimately be able to define genes for migraine and pain diseases. end of study No